Aprea Therapeutics (NASDAQ:APRE) Issues Quarterly Earnings Results

Aprea Therapeutics (NASDAQ:APRE) posted its earnings results on Wednesday. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11, FiscalAI reports. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%.

Aprea Therapeutics Trading Up 2.2%

NASDAQ:APRE traded up $0.01 during trading hours on Wednesday, reaching $0.67. The company had a trading volume of 23,028 shares, compared to its average volume of 1,020,090. The firm has a market cap of $8.36 million, a price-to-earnings ratio of -0.44 and a beta of 1.52. The firm’s 50 day moving average price is $0.71 and its 200-day moving average price is $0.77. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $1.79.

Analysts Set New Price Targets

Several research firms recently commented on APRE. Oppenheimer started coverage on Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price objective on the stock. Wedbush decreased their target price on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.07.

Hedge Funds Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.67% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 34.19% of the stock is currently owned by institutional investors.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.